Clinical trials: Dengue Virus Infection
Dengue, Dengue Fever
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
The aim of this study is to evaluate the immunogenicity and safety of the CYD dengue vaccine in India adult subjects. Primary Objectives: To describe the neutralizing antibody response to each dengue virus serotype before the…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01550289
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
- Where
- 5 sites in India
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Fever
Prospective Surveillance of Febrile Illness for Dengue-Endemic Areas in Asia
The purpose of this study is to detect acute febrile episodes and dengue infection in five Asian countries, to assess dengue seroprevalence, and to assess surveillance infrastructure at investigational sites in anticipation of a…
- Trial name
- NCT01218906
- Where
- 11 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue
An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Brazil
The purpose of this study is to estimate the incidence of dengue infection in children and adults in geographically distinct locations of Brazil.
- Trial name
- NCT01751139
- Testing
- Blood sample collection, Data collection
- Where
- 5 sites in Brazil
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Viral Infection
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
- Trial name
- NCT02696291
- Testing
- UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Dengue, Dengue Fever
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
This is a descriptive prospective community-based seroprevalence study. Primary objective: To determine the prevalence of specific antibodies (immunoglobulin G [IgG]) against dengue in healthy 5 to 10 year-old children in India.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01477671
- Where
- 4 sites in India
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Detection of Dengue Virus in Plasma of Patients in Nepal
To test whether Karius Infectious Disease Diagnostic Sequencing assay can detect Dengue Virus in plasma from suspected cases of Dengue or Dengue Fever like-illnesses from samples collected as part of a hospital-based multi-site…
- Trial name
- NCT03620487
- Where
- Nepal
- Volunteers
- 643 people
- Sponsor
- Karius, Inc.
Dengue
A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan
The goal of this study is to determine the immunogenicity and safety of TV003(TetraVax-DV), a live attenuated tetravalent dengue vaccine candidate, in healthy human subjects in Taiwan
- Trial name
- NCT03485144
- Testing
- TV003
- Where
- Taiwan
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Dengue Fever
Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
The purpose of this study is to assess the safety of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) (previously DENVax) in healthy adults when given as either a subcutaneous (SC) or intradermal (ID) injection at two dose…
- Trial name
- NCT01224639
- Testing
- TDV - Low Dose, TDV - High Dose
- Where
- Colombia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Inviragen Inc.
DENV-3 Controlled Human Infection Model
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
- Trial name
- NCT06799741
- Testing
- AV-1 100 mg, AV-1 300 mg, AV-1 900 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue Fever
Study of HBV-001 D1 in Healthy Adults
This is a single-center, double-blind, randomized, Phase 1 study to assess the safety and tolerability of HBV-001 D1 in healthy adult subjects.
- Trial name
- NCT00936429
- Testing
- DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hawaii Biotech, Inc.
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
The aim of the study was to assess the immune response and the safety of different vaccination schedules of CYD dengue vaccine. The primary objectives of the study were: To demonstrate the non-inferiority of the immune response…
- Trial name
- NCT02628444
- Testing
- CYD Dengue Vaccine
- Where
- 6 sites in Colombia, Philippines
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chikungunya Virus, Dengue Virus
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
The rationale for a Treatment Use Investigational Device Exemption (IDE) of INTERCEPT PCs is to address current gaps in platelet transfusion safety in selected geographic regions.
- Trial name
- TRUE (NCT02305732)
- Testing
- INTERCEPT Platelets
- Where
- 8 sites in Puerto Rico
- Volunteers
- 90 people
- Sponsor
- Cerus Corporation
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue
- Trial name
- NCT01374516
- Testing
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Where
- 22 sites in Brazil, Colombia and 3 more
- Volunteers
- 20,869 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)
The purpose of this study was to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.
- Trial name
- NCT03341637
- Testing
- Tetravalent Dengue Vaccine (TDV)
- Where
- 5 sites in Mexico
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Takeda
Randomised Clinical Trial, Double Blind
Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study. Forty-two flavivirus-naïve adults will be enrolled and will receive 3 administrations of VLPDEN-02 or control at days 0, 28, and 56.
- Conditions
- Randomised Clinical Trial, Double Blind, Dengue, Challenge Test
- Trial name
- NCT07831473
- Testing
- VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VLP Therapeutics
Dengue Virus, Dengue Fever
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: To describe the humoral immune response to dengue before and after each vaccination with…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00788151
- Testing
- CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine
- Where
- Peru
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
IC14 in Adult Patients With Dengue Fever
Randomized, double-blind, placebo-controlled, safety, PK/PD and preliminary efficacy study of intravenous IC14 in adult patients in a dengue-endemic region presenting with fever > 38°C for < 48 hours with a positive NS1 strip…
- Trial name
- NCT03875560
- Testing
- IC14
- Sponsor
- Implicit Bioscience
Dengue, Dengue Fever
Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects
To evaluate effect of previous flavivirus exposure on the safety and immunogenicity of the ChimeriVax™ dengue tetravalent vaccine Primary Objectives: To describe the safety of one injection of ChimeriVax™ dengue tetravalent…
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
- Trial name
- NCT00730288
- Testing
- Chimeric dengue serotype (1, 2, 3, 4)
- Where
- Australia
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sanofi
Malaria Fever, Zika
Xpert® Tropical Fever Test on GeneXpert® Edge X System
This is a multi-site, observational, cross-sectional clinical study that includes geographically diverse sites within and outside the United States.
- Conditions
- Malaria Fever, Zika, Dengue Fever, Leptospirosis
- Trial name
- NCT07520279
- Testing
- Xpert Tropical Fever test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Cepheid
Dengue Virus Infection
Dengvaxia US Pregnancy Registry
The primary objective of this study is to assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women and their offspring(s) vaccinated with Dengvaxia during their pregnancy
- Trial name
- DNG00044 (NCT04486638)
- Testing
- Dengue Tetravalent Vaccine, Live
- Where
- Puerto Rico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company